Novel cholesterol-dependent regulation of cardiac K ATP subunit expression revealed using histone deacetylase inhibitors

• Published in: Physiological reports 2021-01, Vol.8 (24), p.e14675
• Main Authors: Geiger, Robert, Fatima, Naheed, Schooley, Jr, James F, Smyth, Jeremy T, Haigney, Mark C, Flagg, Thomas P
• Format: Article
• Language: English
• Subjects: Animals; Antibodies; Cardiomyocytes; Cardiovascular system; Chlorocebus aethiops; Cholesterol; Cholesterol - metabolism; COS Cells; Experiments; Gene expression; Heart; Histone deacetylase; Histone Deacetylase Inhibitors - pharmacology; Humans; Hydroxamic Acids - pharmacology; Hypercholesterolemia; Hypotheses; Ischemia; Metabolism; Myocytes, Cardiac - drug effects; Myocytes, Cardiac - metabolism; Physiology; Potassium; Proteins; Reporter gene; Sterol Regulatory Element Binding Protein 1 - metabolism; Sterol regulatory element-binding protein; Sterols; Sulfonylurea; Sulfonylurea Receptors - genetics; Sulfonylurea Receptors - metabolism; Transcription factors; Trichostatin A
• ISSN: 2051-817X
• DOI: 10.14814/phy2.14675

We recently discovered that the histone deacetylase inhibitor, trichostatin A (TSA), increases expression of the sulfonylurea receptor 2 (SUR2; Abcc9) subunit of the ATP-sensitive K (K ) channel in HL-1 cardiomyocytes. Interestingly, the increase in SUR2 was abolished with exogenous cholesterol, suggesting that cholesterol may regulate channel expression. In the present study, we tested the hypothesis that TSA increases SUR2 by depleting cholesterol and activating the sterol response element binding protein (SREBP) family of transcription factors. Treatment of HL-1 cardiomyocytes with TSA (30 ng/ml) caused a time-dependent increase in SUR2 mRNA expression that correlates with the time course of cholesterol depletion assessed by filipin staining. Consistent with the cholesterol-dependent regulation of SREBP increasing SUR2 mRNA expression, we observe a significant increase in SREBP cleavage and translocation to the nucleus following TSA treatment that is inhibited by exogenous cholesterol. Further supporting the role of SREBP in mediating the effect of TSA on K subunit expression, SREBP1 significantly increased luciferase reporter gene expression driven by the upstream SUR2 promoter. Lastly, HL-1 cardiomyocytes treated with the SREBP inhibitor PF429242 significantly suppresses the effect of TSA on SUR2 gene expression. These results demonstrate that SREBP is an important regulator of K channel expression and suggest a novel method by which hypercholesterolemia may exert negative effects on the cardiovascular system, namely, by suppressing expression of the K channel.